Qualigen Therapeutics Files 8-K
Ticker: AIXC · Form: 8-K · Filed: Jul 16, 2025 · CIK: 1460702
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Qualigen Therapeutics filed an 8-K on July 16, 2025, likely containing regulatory updates.
AI Summary
On July 16, 2025, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Qualigen Therapeutics, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- July 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 26-3474527 (identifier) — I.R.S. Employer Identification No.
- 5857 Owens Avenue , Suite 300 , Carlsbad , California 92008 (address) — Address of principal executive offices
- (760) 452-8111 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Qualigen Therapeutics, Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on July 16, 2025.
In which state is Qualigen Therapeutics, Inc. incorporated?
Qualigen Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Qualigen Therapeutics, Inc.?
The principal executive office address is 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the telephone number listed for Qualigen Therapeutics, Inc.?
The telephone number listed is (760) 452-8111.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding Qualigen Therapeutics, Inc. (AIXC).